The most recent information on EKOS
Proven to yield safe and effective results, EKOS is changing the standard of care for pulmonary embolism. See the latest clinical studies, webinars, thought-leadership pieces and product updates.
OPTALYSE long-term results show sustained
patient outcomes out to 1 year1
In the OPTALYSE PE study of 101 patients with submassive PE utilizing EKOS therapy, EKOS yielded safe and effective results for acute, massive and submassive PE. It was also shown to quickly improve right ventricular function and pulmonary artery pressure while minimizing the risk of bleeding.1
Now in effect:
A significant reimbursement increase for EKOS procedures
Weighted averages based on distribution of MS-DRGs from CMS’ Final IPPS FY 2021, MedPAR Vol 7b
As of October 1, qualifying PE procedures will increase +151% and qualifying vascular procedures will increase +204%. To help your institution benefit from these new changes, we created an EKOS coding guide. It will show your billers and coders staff how to map the 58 new ICD-10-PCS codes to the appropriate DRGs.
Bilateral PE treatment, simplified
The new EKOS Control Unit 4.0 makes therapy delivery easier than ever.
EKOS Control Unit 4.0 offers new functionality and workflow-based intelligence for EKOS devices both at the procedure table and in the ICU. It’s the result of extensive collaboration with our clinician partners — and it’s a critical part of the EKOS system that continues to break new ground in the treatment of PE.
1. Piazza G, Sterling KM, Tapson VF, Ouriel K, Sharp ASP, Liu P-Y, Goldhaber SZ; OPTALYSE-PE Investigators. One-Year Echocardiographic, Functional, and Quality of Life Outcomes after Ultrasound-Facilitated Catheter-Based Fibrinolysis for Pulmonary Embolism. Circ Cardiovasc Interv. 2020;13:e009012. doi: 10.1161/CIRCINTERVENTIONS.120.009012